SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is an emerging clinical-stage biotech firm that uses AI, bioinformatics, experimental biology, and automation to industrialize drug discovery for various ...

A young computer scientist and two colleagues show that searches within data structures called hash tables can be much faster than previously deemed possible. Sometime in the fall of 2021, Andrew ...

James Jin Kang does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

NVIDIA Co. (NASDAQ: NVDA) is the undisputed leader of the artificial intelligence (AI) revolution. The company envisioned an AI future over 12 years ago and began executing the blueprint for ...

RIYADH, Saudi Arabia & TOKYO--(BUSINESS WIRE)--Recursive Inc. (Headquarters: Shibuya-ku, Tokyo; CEO: Tiago Ramalho; hereinafter referred to as "Recursive"), a developer of AI solutions that facilitate ...

Recursion Pharmaceuticals (NASDAQ:RXRX) on Tuesday announced topline results from its SYCAMORE Phase 2 trial for its most advanced candidate REC-994 in symptomatic cerebral cavernous malformation (CCM ...